ArticlePLoS computational biology2025
Designing diverse and high-performance proteins with a large language model in the loop.
Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A p53Molecular therapy. Oncology · 2026Article
- SPPIDER-seq: sequence-based partner-aware predictor of protein-protein interaction sites.Bioinformatics (Oxford, England) · 2026Article
- SPPIDER-seq: Sequence-based partner-aware predictor of protein-protein interaction sites.bioRxiv : the preprint server for biology · 2026Article
- Accessible, uniform protein property prediction with a scikit-learn based toolset AIDE.Bioinformatics (Oxford, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a protein engineering approach to directed evolution with machine learning that integrates a new semi-supervised neural network fitness prediction model, Seq2Fitness, and an innovative optimization algorithm, biphasic annealing for diverse and adaptive sequence sampling (BADASS) to design sequences. Seq2Fitness leverages protein language models to predict fitness landscapes, combining evolutionary data with experimental labels, while BADASS efficiently explores these landscapes by dynamically adjusting temperature and mutation energies to prevent premature convergence and to generate diverse high-fitness sequences. Compared to alternative models, Seq2Fitness improves Spearman correlation with experimental fitness measurements, increasing from 0.34 to 0.55 on sequences containing mutations at positions entirely not seen during training. BADASS requires less memory and computation compared to gradient-based Markov Chain Monte Carlo methods, while generating more high-fitness and diverse sequences across two protein families. For both families, 100% of the top 10,000 sequences identified by BADASS exceed the wildtype in predicted fitness, whereas competing methods range from 3% to 99%, often producing far fewer than 10,000 sequences. BADASS also finds higher-fitness sequences at every cutoff (top 1, 100, and 10,000). Additionally, we provide a theoretical framework explaining BADASS's underlying mechanism and behavior. While we focus on amino acid sequences, BADASS may generalize to other sequence spaces, such as DNA and RNA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.